412 related articles for article (PubMed ID: 16544267)
1. Extended-spectrum beta-lactamases and clinical outcomes: current data.
Ramphal R; Ambrose PG
Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
5. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Labombardi VJ; Rojtman A; Tran K
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
[TBL] [Abstract][Full Text] [Related]
7. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
9. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
Bhavnani SM; Ambrose PG; Craig WA; Dudley MN; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):231-6. PubMed ID: 16423491
[TBL] [Abstract][Full Text] [Related]
10. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
[TBL] [Abstract][Full Text] [Related]
12. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
Lee SY; Kuti JL; Nicolau DP
J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
14. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
[TBL] [Abstract][Full Text] [Related]
15. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
[TBL] [Abstract][Full Text] [Related]
16. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
Nasa P; Juneja D; Singh O; Dang R; Singh A
Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
[TBL] [Abstract][Full Text] [Related]
17. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
Zarakolu P; Metan G; Hasçelik G; Akova M
Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
[TBL] [Abstract][Full Text] [Related]
18. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
Akyar I
Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
[TBL] [Abstract][Full Text] [Related]
19. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
20. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
